Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
While PRO-CTCAEs capture patient reports of particular symptomatic AEs, the “toxicity over time” approach provides a longitudinal assessment of these AEs.
In this study, claims data from CMS were used to estimate health care utilization of patients with DLCBL before and after CAR-T therapy.
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
Mosunetuzumab may offer a survival benefit, particularly in patients who have relapsed after the receipt of CAR-T.
Patients were randomly assigned to receive either cyclophosphamide followed by cyclosporine A or cyclosporine A plus mucophenolic acid following allogeneic HSCT.
